Kal Ramnarayan
Scientific Tracks Abstracts: Med chem
The entire life sciences industry is focused on only a few hundred protein targets for drug discovery. There are potentially many more novel targets, not only human proteins but also those present in infectious organisms likely to be relevant targets for important new drugs. The abundance of potential drug targets is a challenge for the pharmaceutical and biotech companies that have to focus their resources. At least 50% of all targets that go into HTS screens do not generate significant leads and hence other cost-effective technologies are required to generate novel lead molecules. We have developed a structure-based approach to develop lead molecules in 60 to 90 days, which has resulted in validated lead molecules for a diverse set of drug targets including targets that are involved in protein-protein interaction. Essential ingredients of the technology are: X-ray crystallography, protein modeling, virtual screening, docking and scoring. In this presentation we would like to discuss our technology with specific application examples in protein-protein interactions.
Kal Ramnarayan is the founder, President, Chief Scientific Officer of Sapient Discovery. Previously, he co-founded Structural Bioinformatics, Inc. and Cengent Therapeutics. Prior to Structural Bioinformatics, Inc., he was head of Computational Chemistry at Immuno Pharmaceutics Inc., where he designed numerous drug leads, including highly specific endothelin; a receptor antagonists. This became Sitaxsentan, currently in Phase III clinical development by Encysive Pharmaceuticals. He holds a Ph.D. in Molecular Biophysics from the Indian Institute of Science, Bangalore and has multiple papers and patents and several other patents pending. He is also co-founder of Focus Synthesis, LLC, in San Diego.
Medicinal Chemistry received 6627 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 